The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | Treatment options for high-risk myeloma
Annemiek Broyl
• 5 Oct 2018
Annemiek Broyl, MD, PhD, from Erasmus Medical Center and University, Rotterdam, Netherlands, discusses how to treat high-risk multiple myeloma (MM). Dr Broyl highlights trials such as MUK Nine (NCT03188172)., and emphasizes the importance of reaching for measurable residual disease negativity in this group of patients. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
